D. S. Reich, C. F. Lucchinetti, and P. A. Calabresi, Multiple sclerosis, N. Engl. J. Med, vol.378, pp.169-180, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01480156

N. Dubuisson, F. Puentes, G. Giovannoni, and S. Gnanapavan, Science is 1% inspiration and 99% biomarkers, Mult. Scler. Houndmills Basingstoke Engl, vol.58517, pp.70936-70938, 2017.

G. Disanto, Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis, Ann. Neurol, vol.81, pp.857-870, 2017.

J. Kuhle, Blood neurofilament light chain as a biomarker of MS disease activity and treatment response, Neurology, vol.92, pp.1007-1015, 2019.

N. Siller, Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis, Mult. Scler. J, vol.58518, pp.76566-76572, 2018.

C. Barro, Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis, Brain J. Neurol, 2018.

E. Cantó, Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years, JAMA Neurol, 2019.

D. Jakimovski, Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study, Ann. Clin. Transl. Neurol, vol.6, pp.1757-1770, 2019.

A. Abdelhak, A. Huss, J. Kassubek, H. Tumani, and M. Otto, Serum GFAP as a biomarker for disease severity in multiple sclerosis, Sci. Rep, vol.8, p.14798, 2018.

, Scientific RepoRtS |, vol.10, p.10923, 2020.

H. Högel, Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity, Mult. Scler. Houndmills Basingstoke Engl, 2018.

A. Abdelhak, Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker, Front. Neurol, vol.10, p.280, 2019.

A. J. Thompson, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, Lancet Neurol, vol.17, pp.162-173, 2018.

M. J. Fartaria, Automated detection of white matter and cortical lesions in early stages of multiple sclerosis, J. Magn. Reson. Imaging JMRI, vol.43, pp.1445-1454, 2016.

Y. Wu, Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI, NeuroImage, vol.32, pp.1205-1215, 2006.

M. J. Fartaria, Partial volume-aware assessment of multiple sclerosis lesions, NeuroImage Clin, vol.18, pp.245-253, 2018.

N. Norgren, Neurofilament and glial fibrillary acidic protein in multiple sclerosis, Neurology, vol.63, pp.1586-1590, 2004.

J. Burman, Assessing tissue damage in multiple sclerosis: a biomarker approach, Acta Neurol. Scand, vol.130, pp.81-89, 2014.

M. Watanabe, Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD, Neurology, vol.93, pp.1299-1311, 2019.

M. A. Mañé-martínez, Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis, J. Neuroimmunol, vol.299, pp.112-117, 2016.

M. A. Martínez, Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis, Mult. Scler. J, vol.21, pp.550-561, 2015.

J. Bergman, Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS, Neurol. Neuroimmunol. Neuroinflammation, vol.3, p.271, 2016.